Autobio Diagnostics Co., Ltd.

Equities

603658

CNE100002GC4

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
54.28 CNY +2.03% Intraday chart for Autobio Diagnostics Co., Ltd. +0.37% -4.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Autobio Diagnostics' Q1 Profit Jumps 34% MT
Autobio Diagnostics' 2023 Profit Climbs 4% as Operating Income Stays Flat MT
Autobio Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 21, 2024. CI
Autobio Diagnostics Secures Registration Certificates for 11 Devices MT
Autobio Diagnostics Gets Regulatory Nod in China for 16 Devices MT
Autobio Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on February 20, 2024. CI
Autobio Diagnostics Co., Ltd. authorizes a Buyback Plan. CI
Autobio Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Autobio Diagnostics Co., Ltd.(XSSC:603658) added to S&P Global BMI Index CI
Autobio Diagnostics Logs Low Single-Digit Earnings Growth in H1 MT
Autobio Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Autobio Diagnostics Gets Registration Certificates for Five Devices MT
Shenzhen Meili Namikong Technology Co., Ltd. announced that it has received funding from Autobio Diagnostics Co., Ltd. CI
Autobio Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Autobio Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Autobio Diagnostics Co., Ltd.(XSSC:603658) added to FTSE All-World Index CI
Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on March 19, 2022. CI
Autobio Diagnostics Co., Ltd.'s Equity Buyback announced on March 19, 2022, has closed with 5,260,910 shares, representing 0.90% for CNY 243.27 million. CI
Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on March 19, 2022. CI
Autobio Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on March 19, 2022. CI
Autobio Diagnostics Secure Nine Registration Certificates in China MT
Autobio Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on March 19, 2022. CI
Chart Autobio Diagnostics Co., Ltd.
More charts
Autobio Diagnostics Co., Ltd. is a China-based company and mainly engaged in development, manufacture and sales of diagnostics products. The Company's main products include gnostic products, microbiology detection products, and related devices. The immunodiagnostic products include microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The microbiology detection products include training detection reagents, susceptibility detection reagents and rapid detection reagents. The device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. The Company distributes its products in domestic markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
54.28 CNY
Average target price
62.84 CNY
Spread / Average Target
+15.77%
Consensus
  1. Stock Market
  2. Equities
  3. 603658 Stock
  4. News Autobio Diagnostics Co., Ltd.
  5. Autobio Diagnostics Gets Regulatory Nod in China for 16 Devices